Literature DB >> 2876510

The effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers.

S L Lightman, P Fox, M J Dunne.   

Abstract

The endocrine effect of SMS 201-995, an octapeptide analogue of somatostatin, was assessed during a combined anterior pituitary function test. There was no effect on the extent of hypoglycaemia after intravenous insulin infusion or on the subsequent rate of recovery of plasma glucose. SMS 201-995 administration, however, resulted in a profound and selective suppression of the GH response to hypoglycaemia without affecting the ACTH or cortisol responses. There was also a marked reduction of TSH release in response to intravenous TRH; the prolactin response was unimpaired. The LH response to LHRH was blunted and the FSH response unaffected. SMS 201-995 does not significantly impair the counterregulatory mechanisms in response to hypoglycaemia, and, in particular, the hypothalamic-pituitary-adrenal axis remains intact.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2876510     DOI: 10.3109/00365528609087435

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

1.  Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome.

Authors:  A Brunani; C Crespi; M De Martin; A Dubini; M Piolini; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

2.  Evidence That Endogenous Somatostatin Inhibits Episodic, but Not Surge, Secretion of LH in Female Sheep.

Authors:  Richard B McCosh; Brett M Szeligo; Michelle N Bedenbaugh; Justin A Lopez; Steven L Hardy; Stanley M Hileman; Michael N Lehman; Robert L Goodman
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

Review 3.  Drugs that suppress TSH or cause central hypothyroidism.

Authors:  Bryan R Haugen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

Review 4.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

Review 5.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

6.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

Review 7.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

8.  Measurement of Serum Free Thyroxine Index May Provide Additional Case Detection Compared to Free Thyroxine in the Diagnosis of Central Hypothyroidism.

Authors:  Kevin M Pantalone; Betul Hatipoglu; Manjula K Gupta; Laurence Kennedy; Amir H Hamrahian
Journal:  Case Rep Endocrinol       Date:  2015-12-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.